X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian share markets rule firm 
(Tue, 27 Nov 01:30 pm) 
 
Backed by all-round buying Indian share markets continued to trade higher in the post noon trading session. All the sectoral indices are trading positive with realty, consumer durables and banking stocks leading the gains.

BSE-Sensex is up 253 points and NSE-Nifty is trading up by 73 points. Both BSE Mid Cap and BSE Small Cap indices are trading up by 1% and 0.8%, respectively. The rupee is trading at 55.6 to the US dollar.

Majority of the large IT stocks are trading positive with Moser Baer and Infosys being the biggest gainers. According to a leading financial daily, a study by International Data Corporation (IDC) has projected Latin America to be the next growth driver for the Indian Information Technology (IT) services industry. As per IDC, in the wake of markets stagnating in developed countries, Indian IT companies are increasingly focusing on the Latin American markets where rising economic prosperity is driving demand for technologies like cloud, mobility, big data and social web. Big banks, telecommunication companies and large manufacturers in Latin America have started to outsource their IT operations to meet their rising technology demands. IDC has estimated IT services spending in Latin America to grow at a compounded annual growth rate of 10.8% creating a market opportunity of US$ 40 bn by 2016.

Most of the Indian pharma stocks are trading positive with Fresnius Kabi and Orchid Chemicals, being the biggest gainers. A leading business daily recently reported that Lupin's subsidiary has launched the generic version of the anti-cholestrol drug Tricor in the US market after it received approval from US Food and Drug Administration (USFDA). The firm has lunched fenofibrate tablets which are the generic version of Abott's Tricor tablets in 48 mg and 145 mg strengths. Reportedly, Tricor is being marketed by only three players in the US market namely, Lupin, Teva and Abbott translating into a good revenue driver for Lupin. According to the IMS Health, June 2012 data, Tricor tablets in 48 mg and 145 mg strengths have a market size of US$ 1.26 bn in the US.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian share markets rule firm". Click here!

  
 

S&P BSE SENSEX


Jun 28, 2017 12:37 PM

MARKET STATS